Zhejiang Shengda Bio-Pharm Co., Ltd. Share Price

Equities

603079

CNE100002W43

Food Processing

End-of-day quote Shanghai S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
10.91 CNY +9.98% Intraday chart for Zhejiang Shengda Bio-Pharm Co., Ltd. +17.95% -25.12%

Financials

Sales 2022 738M 102M 8.16B Sales 2023 727M 100M 8.04B Capitalization 2.49B 343M 27.48B
Net income 2022 31M 4.28M 343M Net income 2023 -54M -7.45M -597M EV / Sales 2022 2.52 x
Net cash position 2022 288M 39.76M 3.18B Net cash position 2023 88.29M 12.19M 976M EV / Sales 2023 3.3 x
P/E ratio 2022
69.7 x
P/E ratio 2023
-45.5 x
Employees 1,152
Yield 2022
0.48%
Yield 2023
-
Free-Float 42.01%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
China stocks rise as strength in banks offsets developers' falls RE
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announces an Equity Buyback for CNY 34 million worth of its shares. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announced that it expects to receive CNY 500 million in funding CI
More news
1 day+9.98%
1 week+17.95%
Current month-13.14%
1 month-29.66%
3 months-17.72%
6 months-18.88%
Current year-25.12%
More quotes
1 week
9.03
Extreme 9.03
10.91
1 month
8.70
Extreme 8.7
12.92
Current year
7.01
Extreme 7.01
15.51
1 year
7.01
Extreme 7.01
16.24
3 years
7.01
Extreme 7.01
20.00
5 years
7.01
Extreme 7.01
43.91
10 years
7.01
Extreme 7.01
43.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 12/12/13
Director of Finance/CFO 44 26/04/22
Director/Board Member 38 31/12/11
Members of the board TitleAgeSince
Director/Board Member 64 23/09/13
Director/Board Member 59 17/12/19
Director/Board Member 62 16/09/21
More insiders
Date Price Change Volume
26/04/24 10.91 +9.98% 9,025,532
25/04/24 9.92 +0.92% 2,877,200
24/04/24 9.83 +3.15% 2,799,848
23/04/24 9.53 +1.93% 3,175,948
22/04/24 9.35 +1.08% 3,445,460

End-of-day quote Shanghai S.E., April 25, 2024

More quotes
ZHEJIANG SHENGDA BIO-PHARM CO., LTD. is a China-based company principally engaged in the research, development, production and sales of vitamins and biological preservatives. Its vitamin products mainly include biotin and folic acid. Its biological preservative products mainly include natamycin and nisin. The Company distributes its products in domestic market and to overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 603079 Stock